CA3104568A1 - Melange de molecules d'hydroxypropyl-.beta.-cyclodextrine et son procede de preparation - Google Patents

Melange de molecules d'hydroxypropyl-.beta.-cyclodextrine et son procede de preparation Download PDF

Info

Publication number
CA3104568A1
CA3104568A1 CA3104568A CA3104568A CA3104568A1 CA 3104568 A1 CA3104568 A1 CA 3104568A1 CA 3104568 A CA3104568 A CA 3104568A CA 3104568 A CA3104568 A CA 3104568A CA 3104568 A1 CA3104568 A1 CA 3104568A1
Authority
CA
Canada
Prior art keywords
beta
substance
equal
ppm
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3104568A
Other languages
English (en)
French (fr)
Inventor
Clothilde Buffe
Joel Delattre
Vincent Wiatz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roquette Freres SA
Original Assignee
Roquette Freres SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1855952A external-priority patent/FR3083234B1/fr
Application filed by Roquette Freres SA filed Critical Roquette Freres SA
Publication of CA3104568A1 publication Critical patent/CA3104568A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3104568A 2018-06-29 2019-06-28 Melange de molecules d'hydroxypropyl-.beta.-cyclodextrine et son procede de preparation Pending CA3104568A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR1855952 2018-06-29
FR1855952A FR3083234B1 (fr) 2018-06-29 2018-06-29 Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation
FR1902375 2019-03-08
FR1902375 2019-03-08
PCT/FR2019/051602 WO2020002851A1 (fr) 2018-06-29 2019-06-28 NOUVELLE HYDROXYPROPYL-β-CYCLODEXTRINE ET SON PROCÉDÉ DE PRÉPARATION

Publications (1)

Publication Number Publication Date
CA3104568A1 true CA3104568A1 (fr) 2020-01-02

Family

ID=67551566

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3104568A Pending CA3104568A1 (fr) 2018-06-29 2019-06-28 Melange de molecules d'hydroxypropyl-.beta.-cyclodextrine et son procede de preparation

Country Status (10)

Country Link
US (1) US12522670B2 (https=)
EP (1) EP3814386A1 (https=)
JP (2) JP7581055B2 (https=)
KR (1) KR102912248B1 (https=)
CN (1) CN112334494A (https=)
CA (1) CA3104568A1 (https=)
IL (1) IL279845A (https=)
MX (1) MX2020013689A (https=)
SG (1) SG11202013126QA (https=)
WO (1) WO2020002851A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490691A (zh) 2019-01-03 2021-10-08 劣势者药物有限公司 环糊精二聚体、其组合物及其用途
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
JP2024064599A (ja) * 2022-10-28 2024-05-14 国立大学法人 熊本大学 細胞内コレステロール輸送障害に起因する疾患又は障害の治療、予防又は改善用組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US5096893A (en) 1989-04-03 1992-03-17 The United States Of America As Represented By The Department Of Health And Human Services Regioselective substitutions in cyclodextrins
AU631628B2 (en) * 1989-04-03 1992-12-03 Janssen Pharmaceutica N.V. Regioselectively hydroxyalkylated cyclodextrins and process therefor
KR920008700A (ko) * 1990-10-29 1992-05-28 이헌조 데크의 테이프 삽입유무 표시방법
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
CN1155888A (zh) 1995-06-08 1997-07-30 火箭兄弟公司 粉状羟丙基-β-环糊精组合物和其制备方法
FR2735136B1 (fr) * 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
FR2738149B1 (fr) * 1995-09-06 1997-11-14 Chauvin Lab Sa Collyre a base d'indometacine pret a l'emploi
US5744154A (en) 1995-09-06 1998-04-28 Laboratoire Chauvin S.A. Ready-to-use indomethacin-based eye lotion
EP1655034A1 (en) * 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
PH12013500477A1 (en) 2010-09-13 2018-01-17 Bev Rx Inc Aqueous drug delivery system comprising off-flavor masking agent
CN102558394B (zh) 2010-12-07 2014-11-12 石药集团中奇制药技术（石家庄）有限公司 羟丙基-β-环糊精的制备方法
CN102040675B (zh) * 2010-12-22 2012-10-03 石药集团中诺药业（石家庄）有限公司 一种羟丙基-β-环糊精的制备方法
ES2547920T3 (es) * 2011-07-01 2015-10-09 Fondazione Istituto Insubrico Di Ricerca Per La Vita Un complejo de tomoxiprol amorfo y ciclodextrina con una rápida velocidad de disolución y procedimiento para su preparación
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
JP2018517046A (ja) * 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法
CN108034010A (zh) * 2017-12-29 2018-05-15 山东滨州智源生物科技有限公司 一种羟丙基环糊精的绿色制备方法

Also Published As

Publication number Publication date
IL279845A (en) 2021-03-01
JP7581055B2 (ja) 2024-11-12
US12522670B2 (en) 2026-01-13
US20210253746A1 (en) 2021-08-19
MX2020013689A (es) 2021-05-12
SG11202013126QA (en) 2021-02-25
KR20210027279A (ko) 2021-03-10
JP2021529243A (ja) 2021-10-28
EP3814386A1 (fr) 2021-05-05
JP2024150779A (ja) 2024-10-23
CN112334494A (zh) 2021-02-05
KR102912248B1 (ko) 2026-01-15
WO2020002851A1 (fr) 2020-01-02

Similar Documents

Publication Publication Date Title
US20050222086A1 (en) Alprazolam inclusion complexes and pharmaceutical composition thereof
JP2024150779A (ja) 新規なヒドロキシプロピル－β－シクロデキストリン及びそれを生成するための方法
FR2808691A1 (fr) Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
EP0736044B1 (fr) Derives de cyclodextrine, utilisables pour solubiliser des composes chimiques hydrophobes tels que des medicaments, et leurs procedes de preparation
WO2004006897A1 (fr) Dispersions aqueuses de particules nanometriques ou micrometriques pour l'encapsulation de composes chimiques
EP3362487B1 (fr) Nouvelles cyclodextrines méthylées et leurs procédés de préparation
EP1974751A1 (en) Formulations for non-steroidal anti-inflammatory drugs
EP1434567B1 (fr) Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique
EP2595625B1 (en) Pharmaceutical composition containing a tryptophan derivative
EP1469823B1 (fr) Utilisation cosmetique ou dermatologique de la vitamine a ou de ses esters, en association avec une beta-cyclodextrine partiellement methylee
CA2712414C (en) Pharmaceutical composition comprising a .beta.-adrenoreceptor antagonist and a cyclodextrin
Pandey et al. Cyclodextrin based nanoparticles for improved solubility and drug delivery
FR3083234A1 (fr) Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation
WO2022122992A1 (fr) Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable
WO2002083632A1 (fr) Complexes d'anilides et de cyclodextrines, leur preparation et leur application en tant que medicament en particulier pour le traitement des dislipidemies
CA2039120C (fr) Complexes de l'acide tiaprofenique ou de ses esters insolubles ou partiellement solubles avec les cyclodextrines ou leurs derives
WO2025191383A1 (fr) Assemblage moléculaire pour l'encapsulation de molécules hydrophobes, ledit assemblage ayant les molécules hydrophobes encapsulées, procédés de fabrication correspondants et utilisations
WO2021069836A1 (fr) Masquage du goût de l'isosorbide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220908

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240821

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250206

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250610

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250610

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250620

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250620

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20251125

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251218

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251218

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260420

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260420